We are live on ! Find out more
XTLB

XTL Biopharmaceuticals
XTLB

4 hedge funds and large institutions have $483K invested in XTL Biopharmaceuticals in 2014 Q1 according to their latest regulatory filings, with 1 funds opening new positions, 1 increasing their positions, reducing their positions, and 0 closing their positions.

New
Increased
Maintained
Reduced
Closed

33% more funds holding

Funds holding: 3 → 4 (+1)

28% more capital invested

Capital invested by funds: $378K → $483K (+$105K)

0.01% more ownership

Funds ownership: 0.48% → 0.49% (+0.01%)

Holders
4
Holders Change
+1
Holders Change %
+33.33%
% of All Funds
0.12%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
1
Reduced
–
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
U
UBS
Switzerland
+$6K
2
TRCT
Tower Research Capital (TRC)
New York
+$506

Top Sellers

No sellers this quarter

XTLB Hedge Fund Activity: Q1 2014 in Review

4 of the 3,475 institutional investors tracked by Wall St. Rank reported a position in XTL Biopharmaceuticals (XTLB) for Q1 2014, worth a combined $483K — up 28% from $378K a quarter earlier.

Buyers outnumbered sellers: 1 fund opened new XTLB positions and 0 closed out — a net gain of 1 holder — while 1 added to existing stakes and 0 trimmed.

The largest buyer was UBS, opening a new position worth an estimated $6K.

  • 4 institutional investors held XTL Biopharmaceuticals (XTLB) as of Q1 2014, up from 3 in Q4 2013.
  • Funds reported $483K of XTL Biopharmaceuticals stock for Q1 2014, up 28% quarter-over-quarter.
  • 1 fund opened new XTL Biopharmaceuticals positions in Q1 2014 and 0 closed out, a net change of +1 holder.
  • The largest XTL Biopharmaceuticals buyer in Q1 2014 was UBS, an estimated $6K added.

Based on aggregated 13F filings for Q1 2014.